Nonsteroidal anti-inflammatory drugs: A critical review on current concepts applied to reduce gastrointestinal toxicity

Current Medicinal Chemistry

Volumn 16, Issue 16, 2009, Pages 2042-2063

  Abdel Tawab, Mona ^a   Zettl, Heiko ^b   Schubert Zsilavecz, Manfred ^a,b  

^a ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

5 Lipoxygenase; CINODs; Cyclodextrins; Cyclooxygenase; Gastrointestinal toxicity; mPGES 1; NSAIDs; Phospholipids

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [4 (1 HYDROXYIMINO)ETHYLPHENYL] 4 (4 METHANESULFONYLPHENYL)2[5H]FURANONE; 3 [4 (3 HYDROXYIMINOBUT 1YNYL)PHENYL] 4 (4 METHANESULFONYLPHENYL) 2[5H]FURANONE; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARACHIDONATE 5 LIPOXYGENASE; ATB 337; ATB 343; ATM 337; BENZYLHYDROXYL[1 [4 [4 [4 (METHANESULFONYL)PHENYL] 2 OXO 2,5 DIHYDROFURAN 3 YL]PHENYL]ETHYL] CARBAMATE; CYCLODEXTRIN; CYCLOOXYGENASE 2 INHIBITOR; DIARYLPROP 2 YN 1 ONE DERIVATIVE; DICLOFENAC; FURAZAN DERIVATIVE; HYDROGEN SULFIDE; INTESTINAL TREFOIL FACTOR; LICOFELONE; LIPOXYGENASE INHIBITOR; N [5 (4 FLUOROPHENOXY) 2 THIENYL]METHANESULFONAMIDE; NITRIC OXIDE DONOR; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PIRINIXIC ACID; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; COMPLEX FORMATION; CROSS LINKING; DILUTION; DRUG BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSFORMATION; ESTERIFICATION; GASTROINTESTINAL TOXICITY; HUMAN; HYDROPHOBICITY; IC 50; MUCUS SECRETION; NONHUMAN; OSTEOARTHRITIS; PROSTAGLANDIN METABOLISM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SLOW DRUG RELEASE; STOMACH DISEASE; STOMACH MUCOSA; STOMACH MUCOSA LESION; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; TISSUE BLOOD FLOW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG TOXICITY; ENZYME INHIBITORS; GASTROINTESTINAL TRACT; HUMANS; STOMACH DISEASES;

EID: 68449096860     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682209     Document Type: Review

References (135)

1. Jones, R.; Rubin, G.; FRCGP, Berenbaum, F.; Scheiman, E. Gastrointestinal and cardiovascular risks of nonsteroidal antiinflammatory drugs. Am. J. Med., 2008, 121, 464-474.
2. Singh, G. Recent considerations in nonsteroidal anti-inflammatory drugy gastropathy. Am. J. Med., 1998, 105, 31S-38S.
3. Delco, F.; Michetti, P.; Beglinger, C.; Fried, M.; Szucs, T.D. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population based study in Switzerland. Digestion, 2004, 69, 10-19.
4. Raskin, J.B. Gastrointestinal effects of nonsteroidal antiinflammatory therapy. Am. J. Med., 1999, 106, 3S-12S.
5. Giraud, M.N.; Sanduja, S.K.; Felder, T.B.; Illich, P.A.; Dial, E.J.; Lichtenberger L.M. Effect of omeprazole on the bioavailability of unmodified and phospholipids-complexed aspirin in rats. Aliment. Pharmcol. Ther., 1997, 11, 899-906.
6. Bertolini, A.; Ottani, A.; Sandrini, M. Dual acting anti-inflammtory drugs: A reappraisal. Pharmacol. Res. 2001, 44, 437-450.
7. Florence, A. Novel drug formulations: Their potential in modulating adverse effects. Drug Safety, 1994, 10, 233-266
8. Kelly, J.P.; Kaufman, D.W.; Jurgelon, J.M.; Sheehan, J.; Koff, R.S.; Shapiro, S. Risk of aspirin-associated major upper gastrointestinal bleeding with enteric coated or buffered product. Lancet, 1996, 348, 1413-1416.
9. Davies, N.M. Sustained release and enteric coated NSAIDs: Are they really GI safe? J. Pharm. Sci., 1999, 2, 5-14.
10. Genta, I.; Perugini, P.; Pavanetto, F. Different molecular weight chitosan microspheres: Fluence on drug loading and drug release. Drug. Dev. Ind. Pharm., 1998, 24, 779-784.
11. Vane, J. Towards a better aspirin. Nature, 1994, 367, 215-216.
12. Wang, D.; Mann, J.R.; DuBois, R.N. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology, 2005, 128, 1445-1461.
13. Marnett, L.J.; Kalgutkar, A.S. Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. Curr. Opin.Chem. Biol., 1998, 2, 482-490.
14. Coruzzi, G.; Venturi, N.; Spaggiari, S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: Selective COX-2 inhibitors and beyond. Acta Biomed., 2007, 78, 96-110.
15. Kurumbail, R.G.; Stevens, A.M.; Gierse, J.K.; McDonald, J.J.; Stegeman, R.A.; Pak, J.Y.; Gildehaus, D.; Miyashiro, J.M.; Penning, T.D.; Seibert, K.; Isakson, P.C.; Stallings, W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 1996, 384, 644-648.
16. Silverstein, F.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawel; N.M.; Stenson, W.F.; Burr, A.M.; Zhao, W.W.; Kent, J.D.; Lefkowith, J.B.; Verburg, K.M.; Geis, G.S. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA, 2000, 284, 1247-1255.
17. Farooq, M.; Haq, I.; Qureshi, A.S. Cardiovascular risks of COX inhibition: Current perspectives. Expert Opin. Pharmacother., 2008, 9, 1311-1319.
18. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M.B., Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343, 1520-1528.
19. Solomon, S.D.; McMurray, J.J.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 2005, 352, 1071-1080.
20. Graham, D.J.; Campen, D.; Hui, R.; Spence, M.; Cheetham, C.; Levy, G.; Shoor, S.; Ray, W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case control study. Lancet, 2005, 365, 475-481.
21. Jones, R.; Rubin, G.; Berenbaum, F.; Scheiman, J. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am. J. Med., 2008, 121, 464-474.
22. Ham, M.; Kaunitz, J.D. Gastroduodenal defense. Curr. Opin. Gastroenterol., 2007, 23, 607-616.
23. Elliott, S.N.; Wallace, J.L. Nitric oxide: A regulator of mucosal defense and injury. J. Gastroenterol., 1998, 33, 792-803.
24. Wallace, J.L. Mechanisms of protection and healing: Current knowledge and future research. Am. J. Med., 2001, 110, 19S-23S.
25. Becker, J.C.; Domschke, W.; Pohle, T. Current approaches to prevent NSAID-induced gastropathy - COX selectivity and beyond. Brit. J. Clin. Pharmacol., 2004, 58, 587-600.
26. Lichtenberger, L.M.; Romero, J.J.; Dial, E.J. Surface phospholipids in gastric injury and protection of when a selective cyclooxygenase-2 inhibitor (coxib) is used in combination with aspirin. Br. J. Pharmacol., 2007, 150, 913-919.
27. Lichtenberger, L.M. Where is the evidence that cyclooxgenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol., 2001, 61, 631-637.
28. Wallace, J.L.; McKnight, W.K.; Vergnolle, N. Inhibition of both cyclooxygenase (COX-1) and (COX-2) is required for NSAID-induced erosion formation. Gastroenterology, 2000, 118, A194.
29. Langenbach, R.; Morham, S.G.; Tiano, H.F.; Loftin, C.D.; Ghanayem, B.I.; Chulada, P.C.; Mahler, J.F.; Lee, C.A.; Goulding, E.H.; Kluckman, K.D.; Kim, H.S.; Smithies, O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced inflammation and indomethacin induced gastric ulceration. Cell, 1995, 83, 483-492.
30. Lichtenberger, L.M.; Wang, Z-M.; Romero, J.J.; Ulloa, C.; Perez, J.C.; Giraud, M.-N.; Baretto, J.C. Nonsteroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat. Med., 1995, 1, 154-158.
31. Giraud, M.-N.; Motta, C.; Romero, J.J.; Bommelaers, G.; Lichtenberger, L.M. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: A possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatroy drugs (NSAIDs). Biochem. Pharmacol., 1999, 57, 247-254.
32. Lichtenberger, L.M.; Zhou, Y.; Raphael, R.M. NSAID injury to the gastrointestinal tract: Evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J. Pharm. Pharmacol., 2006, 58, 1421-1428.
33. Dial, E.J.; Darling, R.L.; Lichtenberger, L.M. Importance of biliary excretion of indomethacin in gastrointestinal and hepatic injury. J. Gastroenterol. Hepatol., 2008, 23, e384-e389.
34. Lichtenberger, L.M.; Ulloa, C.; Vanous, A.L.; Romero, J.J.; Dial, E.J.; Illich, P.A.; Walters, E.T. Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. J. Pharm. Exp. Ther., 1996, 277, 1221-1227.
35. Anand, B.S.; Romero, J.J.; Sanduja, S.K.; Lichtenberger, L.M. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am. J. Gastroenterol., 1999, 94, 1818-1822.
36. Khazaeinia, T.; Jamali, F. A comparison of gastrointestinal permeabiltiy induced by diclofenac-phospholipid complex with diclofenac acid and its sodium salt. J. Pharm. Pharmaceut. Sci., 2003, 6, 352-359.
37. Lichtenberger, L.M.; Romero, J.J.; De Ruijter, W.M.J.; Behbod, F.; Darling, R. Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: Relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J. Pharm. Exp. Ther., 2001, 298, 279-287.
38. 1H NMR investigation on interaction between ibuprofen and lipoproteins. Chem. Phys. Lip., 2007, 148, 105-111.
39. Lichtenberger, L.M.; Romero, J.J.; Wang, Z.M. ASA forms an ionic complex with phosphatidycholine: Possible molecular explanation for its ulcergenic action. Gastroenterology, 1993, 104, A134, AGA Abstracts.
40. Kurinets, A.; Lichtenberger, L.M. Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats. Dig. Dis. Sci., 1998, 43, 786-790.
41. Giraud, M.N.; Barreto, J.C.; Lichtenberger, L.M. Zwitterionic phospholipids facilitate the transport of aspirin (ASA) across artificial membranes. Gastroenterology, 1995, 108, A101, AGA Abstracts.
42. Lichtenberger, L.M.; Romero, J.J.; Ulloa, C. NSAIDs complexed to phosphatidylcholine (PC) have reduced GI toxicity and enhanced bioavailability. Gastroenterology, 1995, 108, A149, AGA Abstracts.
43. Lichtenberger, L.M.; Ulloa, C.; Romero, J.J.; Vanous, A.L.; Illich, P.A.; Dial, E.J. Nonsteroidal anti-inflammatory drug and phospholipids prodrugs: Combination therapy with antisecretory agents in rats. Gastroenterology, 1996, 111, 990-995.
44. Giraud, M.-N.; Sanduja, S.K.; Felder, T.B.; Illich, P.A.; Dial, E.J.; Lichtenberger, L.M. Effect of omeprazole on the bioavailability of ummodified and phospholipid-complexed aspirin in rats. Aliment. Pharmacol., 1997, 11, 899-906.
45. Lichtenberger, L.M.; Romero, J.J.; Dial, E.J. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (coxib) is used in combination with aspirin. Br. J. Pharmacol., 2007, 150, 913-919.
46. Dunjic, B.S.; Axelson, J.; Ar'Rajab, A.; Larsson, K.; Bengmark, S. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. Scan. J. Gastroenterol., 1993, 28, 89-94.
47. Dvir, E.; Friedman, J.E.; Lee, J.Y.; Koh, J.Y.; Younis, F.; Raz, S.; Shapiro, I.; Hoffman, A.; Dahan, A.; Rosenberg, G.; Angel, I.; Kozak, A.; Duvdevani, R. A novel phospholipid derivative of indomethacin, DP-155 mixture of of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl-5methoxy-2-methyl-3-indolyl acetamidohexanoyl}-sn-glycero-3-phosphatidyl choline], shows superior safety and similar efficacy in reducing brain amyloid β in an Alzheimer's disease model. J. Pharmacol. Exp. Ther., 2006, 318, 1248-1256.
48. Dahan, A.; Duvdevani, R.; Shapiro, I.; Elmann, A.; Finkelstein, E.; Hoffman, A. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithinvalproic acid conjugate following oral administration. J. Con. Rel., 2008, 126, 1-9.
49. Challa, R.; Ahuja, A.; Ali, J.; Khar, R.K. Cyclodextrins in drug delivery: An updated review. AAPS Pharm. Sci. Tech., 2005, 6, E329-E357.
50. Diaz, D.; Escobar, L.C.M.; Bernad, M.J.B. Study of the binding in an aqueous medium of inclusion complexes of several cyclodextrins onvolving fenoprofen calcium. Drug Dev. Ind. Pharm., 1999, 25, 107-110.
51. 1H-NMR study of the inclusion processes for α-and γ-cyclodextrin with fenbufen. Biopolymers, 2005, 77, 361-367.
52. Redenti, E.; Szente, L.; Szejtli. J. Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J. Pharm. Sci., 2001, 90, 979-986.
53. Mura, P.; Faucci, M.T.; Parrini, P.L.; Furlanetto, S.; Pinzauti, S. Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. Int. J. Pharm., 1999, 179, 117-128.
54. Xiliang, G.; Yu, Y.; Guoyan, Z.; Goumei, Z.; Jianbin, C.; Shaomin, S. Study on inclusion interaction of piroxicam with beta-cyclodextrin derivatives. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2003, 59, 3379-3386.
55. Lee, C.R.; Balfour, J.A. Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states. Drugs, 1994, 48, 907-929.
56. Naidu, N.B.; Chowdary, K.P.; Murthy, K.V.; Satyanarayana, V.; Hayman, A.R.; Becket, G. Physiscochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J. Pharm. Biomed. Anal., 2004, 35, 75-86.
57. Ghorab, M.M.; Abdel-Salam, H.M.; El-Sayad, M.A.; Mekhel, M.M. Tablet formulation containing meloxicam and betacyclodextrin: Mechanical characterization and bioavailability evaluation. AAPS Pharm. Sci. Tech., 2004, 5, E59.
58. Larrucea, E.; Arellano, A.; Santoyo, S.; Ygartua, P. Study of the complexation behaviour of tenoxicam with cyclodextrins in solution: improved solubility and percutaneous permeability. Drug Dev. Ind. Pharm., 2002, 28, 973-982.
59. Mura, P.; Furlanetto, S.; Cirri, M.; Maestrelli, F.; Corti, G.; Pinzauti, S. Interaction of naproxen with ionic cyclodextrins in aqueous solution and in the solid state. J. Pharm. Biomed. Anal., 2005, 37, 987-994.
60. Jambhekar, S.; Casella, R.; Maher, T. The physicochemical characteristics and bioavailability of indomethacin from betacyclodextrin, hydroxyethyl-beta-cyclodextrin, and hydroxypropyl-beta-cyclodextrin complexes. Int. J. Pharm., 2004, 270, 149-166.
61. Arancibia, J.A.; Escandar, G.M. Complexation study of diclofenac with beta-cyclodextrin and spectrofluorimetric determination. Analyst, 1999, 124, 1833-1838.
62. Tros de Ilarduya, M.C.; Martín, C.; Goni, M.M.; Martínez-Ohárriz, M.C. Solubilization and interaction of sulindac with beta-cyclodextrin in the solid state and aqueous solution. Drug Dev. Ind. Pharm., 1998, 24, 301-306.
63. Nalluri, B.N.; Chowdary, K.P.R.; Murthy, K.V.R.; Hayman, A.R.; Becket, G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS Pharm. Sci. Tech., 2003, 4, E2.
64. Veiga, M.D.; Merino, M. Interactions of oxyphenbutazone with different cyclodextrins in aqueous medium and in the solid state. J. Pharm. Biomed. Anal., 2002, 28, 973-982.
65. Henry, D.; Lim, L.L.-Y.; Rodriguez, L.A.G.; Gutthann, S.P.; Carson, J.L.; Griffin, M.; Savage, R.; Logan, R.; Moride, Y.; Hawkey, C.; Fries, J.T. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ, 1996, 312, 1563-1566.
66. Warrington, S. Effects of piroxicam-beta-cyclodextrin on the gastrointestinal tract. Eur. J. Rheumatol. Inflamm., 1993, 12, 29-37.
67. Fukahori, T.; Kondo, M.; Nishikawa, S. Dynamic study of interaction between β-cyclodextrin and aspirin by the ultrasonic relaxation method. J. Phys. Chem., 2006, 110, 4487-4491.
68. Nagarsenker, M.S.; Joshi, M.S. Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage. Drug Dev. Ind. Pharm., 2005, 31, 169-178
69. Acosta, G., Linared, D.; Oleina, R.; Martinez, L.D.; Gomez, M.R. Determination of the binding constant of indomethacin-beta-cyclodextrin complex by capillary electrophoresis: Experimental optimization and temperature study. Pharmazie, 2007, 62, 847-52.
70. Fronza, G.; Mele, A.; Redenti, E.; Ventura, P. Proton nuclear magnetic resonance spectroscopy studies of the inclusion complex of piroxicam with beta-cyclodextrin. J. Pharm. Sci., 1992, 81, 1162-1165.
71. Pijak, M.R.; Turcani, P.; Turcaniova, Z.; Buran, I.; Gogolak, I.; Mihal, A.; Gazdik, F. Efficacy and tolerability of piroxicam-beta-cyclodextrin in the outpatient management of chronic back pain. Bratisl. Lek. Listy., 2002, 103, 467-472.
72. Lu, W.-L.; Zhang, Q.; Zheng, L.; Wang, H.; Li, R.-Y.; Zhang, L.-F.; Shen, W.-B.; Tu, X.-D. Antipyretic, analgesic and anti-inflammatory activities of ketoprofen β-cyclodextrin inclusion complexes in animals. Biol. Pharm. Bull., 2004, 27, 1515-1520
73. Serni, U. Rheumatic diseases-clinical experience with piroxicambeta cyclodextrin. Eur. J. Rheumatol. Inflamm., 1993, 12, 47-54.
74. Warrington, S.; Debbas, N.; Farthing, M.; Horton, M.; Umile, A. Piroxicam-beta-cyclodextrin: Effects on gastrointestinal blood loss and gastric mucosal appearance in healthy men. Int. J. Tissue React., 1991, 13, 243-248.
75. Coruzzi, G.; Venturi, N.; Spaggiari, S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: Selective COX-2 inhibitors and beyond. Acta Biomed., 2007, 78, 96-110.
76. Stefano, F.; Distrutti E. Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: A review of their current status. Curr. Top Med. Chem., 2007, 7, 277-282.
77. Cena, C.; Lolli, M.L.; Lazzarato, L.; Guaita, E.; Morini, G.; Corazzi, G.; McElroy, S.P.; Megson, I.L., Fruttero, R.; Gasco, A. Anti-inflammatory, gastrosparing, and antiplatelet properties of new NO-donors of aspirin. J. Med. Chem., 2003, 46, 747-754.
78. Wallace, J.L; Ignarro, L.J.; Fiorucci, S. Potential cardioprotective actions of NO-releasing aspirin. Nat. Rev. Drug Discov., 2002, 1, 375-382.
79. Carini, M.; Aldini, G.; Orioli, M.; Piccoli, A.; Rossoni, G.; Facino, R.M. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci., 2004, 74, 3291-3305.
80. Chiroli, V.; Benedini, F.; Ongini, E.; Del Soldato, P. Nitric-oxide-donating non-steroidal anti-inflammatory drugs: The case of nitroderivatives of aspirin. Eur. J. Med. Chem., 2003, 38, 441-446.
81. Gresele, P.; Momi, S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc. Drug Rev., 2006, 24, 148-168.
82. Fiorucci, S.; Santucci, L.; Gresele, P.; Faccino, R.M.; Del Soldato, P.; Morelli, A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. Gastroenterolgy, 2003, 124, 600-607.
83. Fiorucci, S.; Santucci, L.; Distrutti, E. NSAIDs, coxibs, CINODs and H2S-releasing NSAIDs: What lies beyond the horizon. Digest Liver Dis., 2007, 39, 1043-1051.
84. Bandarage, U.K.; Chen L.; Fang, X.; Garvay, D.S.; Glavin, A.; Janero, D.R.; Letts, L.G.; Mercer G.J.; Saha J.K.; Schroeder J.D.; Shumway M.J.; Tam, S.W. Nitrosothiol esters of diclofenac: Synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem., 2000, 43, 4005-4016.
85. Burgaud, J.-L.; Ongini, E.; Del Soldato, P. Nitric oxide-releasing drugs - a novel class of effective and safe therapeutic agents. Ann. N.Y. Acad. Sci., 2002, 962, 360-371.
86. Keeble, J.E.; Moore, P.K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related ncitric-oxide-donating drugs. Brit. J. Pharmacol., 2002, 137, 295-310.
87. Csont, T.; Ferdinandy, P. Cardioprotective effects of glyceryl trinitrate: Beyond vascular nitrate tolerance. Pharmacol. Ther., 2005, 105, 57-68.
88. Lolli, M.L.; Cena, C.; Melena C.; Lazzarato, L.; Morini, G.; Corazzi, G.; Manarini, S.; Fruttero, R.; Gasco, A. A new class of ibuprofen derivatives with reduced gastrotoxicity. J. Med. Chem., 2001, 44, 3463-3468.
89. Gasco, A.; Fruttero, R.; Rolando, B. Focus on recent approaches for the development of new NO-donors. Mini Rev. Med. Chem., 2005, 5, 217-229.
90. Turnball, C.M.; Cena, C.; Fruttero, R.; Gasco, A.; Rossi, A.G.; Megson, I.L. Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. Br. J. Pharmacol., 2006, 148, 517-526.
91. Del Grosso, E.; Boschi, D.; Lazzarato, L.; Cena, C.; Di Stilo, A.; Fruttero, R.; Moro, S.; Gasco, A. The furoxan system: Design of selective nitric peroxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasoldilating activities. Chem. Biodiv., 2005, 2, 886-900.
92. Velázquez, C.; Rao, P.N.P.; Knaus, E.E. Novel nonsteroidal anti-inflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: Design, synthesis, biological evluation, and nitric oxide release studies. J. Med. Chem., 2005, 48, 4061-4067.
93. Bonina, F.; Puglia, C.; Santagati, N.A.; Saija, A.; Tomaino, A.; Tita, B. Oligoethylene ester derivatives of ketoprofen, naproxen and diclofenac as oral prodrugs: A pharmacological evaluation. Pharmazie, 2002, 57, 552-555.
94. Wallace, J.L.; Elliott, S.N.; Del Soldato, P.; McKnight W., Sannicolo, F.; Cirino, G. Gastrointestinal sparing anti-inflammatory drugs: The development of nitric-oxide releasing NSAIDs. Drug Dev. Res., 1998, 42, 144-149.
95. Wallace, J.L.; Reuter, B.; Cicala, C.; McKnight W., Grisham, M.B.; Cirino, G. Novel anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterolgy, 1994, 107, 173-179.
96. Wallace, J.L. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol. Sci., 2007, 28, 501-505.
97. Wallace, J.L.; Caliendo, G.; Santagada, V.; Cirino, G.; Fiorucci, S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen-sulfide releasing diclofenac derivative in the rat. Gastroenterology, 2007, 132, 261-271.
98. Leone, S.; Ottani, A.; Bertolini, A. Dual acting anti-inflammatory drugs. Curr. Top. Med. Chem., 2007, 7, 265-275
99. Steinhilber, D. 5-Lipoxygenase: A target for antiinflammatory drugs revisited. Curr. Med. Chem., 1999, 6, 71-85.
100. Werz, O.; Steinhilber, D. Development of 5-lipoxygenase inhibitors - lessons from cellular enzyme regulation. Biochem. Pharmacol., 2005, 70, 327-333.
101. Celotti, F.; Laufer, S. Anti-inflammatory drugs: New multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res., 2001, 43(5), 429-436.
102. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem., 2003, 38, 645-659.
103. Julément, F.; Dogné, J.-M.; Pirotte, B.; de Leval, X. Recent developments in the field of dual COX/5-LOX inhibitors. Mini Rev Med. Chem., 2004, 4, 633-638.
104. Koeberle, A.; Siemoneit, U.; Bühring, U.; Northoff, H.; Laufer, S.; Albrecht, W.; Werz, O. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prosta-glandin E2 synthase-1. J. Pharmacol. Exp. Ther., 2008, 326, 975-982.
105. Tam, S.S.C.; Lee, D.H.S.; Wang, E.Y.; Munroe, D.G. Tepoxalin, a novel dual inhibitor of the prostaglandinH synthase cyclooxygenase and peroxidase activities. J. Biol. Chem., 1995, 23, 13948-13955.
106. Barbey, S.; Goossens, L.; Taverne, T.; Cornet, J.; Choesmel, V.; Rouaud, C.; Gimeno, G.; Yannic-Arnoult, S.; Michaux, C.; Charlier, C.; Houssin, R.; Hénichart, J.-P. Synthesis and activity of new methoxytetrahydropran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett., 2002, 12, 779-782.
107. Weisman, S.M.; Doyle, M.J.; Wehmeyer, K.R.; Hynd, B.A.; Eichhold, T.H.; Clear, R.M.; Coggeshall, C.W.; Kuhlenbeck, D.L. Effects of tebufelone (NE-11740), a new anti-inflammatory drug, on arachidonic acid metabolism. Agents Actions, 1994, 41, 156-163.
108. Chen, Q.-H.; Rao, P.N.P.; Knaus, E.E. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs). Bioorg. Med. Chem., 2006, 14, 7898-7909.
109. Vila, L. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med. Res. Rev., 2004, 24, 399.
110. Gambaro, G. Strategies to safely interfere with prostanoid activity while avoiding adverse renal effects: Could COX-2 and COX-LOX dual inhibition be the answer? Nephrol. Dial. Transplant., 2002, 17, 1159-1162.
111. Ruiz, J.; Pérez, C.; Pouplana, R. QSAR study of dual cyclooxy-genase and 5-lipoxygenase inhibitors 2,6-di-tert-butylphenol derivatives. Bioorg. Med. Chem., 2003, 11, 4207-4216.
112. Moreau, A.; Rao, P.N.P.; Knaus, E. Synt hesis and biological evaluation of acyclic triayryl (Z)-olefins possessing a 3,5-di-tert-butyl-4-hydroxyphenyl pharmacophore: Dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg. Med. Chem., 2006, 14, 5340-5350.
113. Janusz, J.M.; Young, P.A.; Ridgeway, J.M.; Scherz, M.W.; Enzweiler, K.; Wu, L.I.; Gan, L.G.; Chen, J.; Kellstein, D.E.; Green, S.A.; Tulich, J.L.; Rosario-Jansen, T.; Magrisso, I.J.; Wehmeyer, K.R.; Kuhlenbeck, D.L.; Eichhold, T.H.; Dobson, R.L.M. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3.7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofiran derivatives as gastrointestinal safe anti-inflammatory and analgesic agents: Variations at the 5 position. J. Med. Chem., 1998, 41, 3515-3529.
114. Zheng, M.; Zhang, Z.; Zhu, W.; Liu, H.; Luo, X.; Chen, K.; Jiang, H. Essential structural profile of a dual functional inhibtor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): Molecular docking and 3D-QSAR analyses on DHDMBF analogues. Bioorg. Med. Chem., 2006, 14, 3428-3437.
115. Pillai, A.D.; Rathod, P.D.; Xavier, F.P.; Padh, H.; Sudarsanam, V.; Vasu, K.K. Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design. Bioorg. Med. Chem., 2005, 13, 6685-6692.
116. Reddy, M.V.R.; Billa, V.K.; Pallela, V.R.; Mallireddigari, M.R.; Boominathan, R.; Gabriel, J.L.; Reddy, E.P. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg. Med. Chem., 2008, 16, 3907-3916.
117. Rao, P.N.P.; Chen, Q.-H.; Knaus, E.E. Synthesis and structure - activity relationship of 1,3-diarylprop-2-yn-1-ones: Dual inhibitors of cyclooxygenases and lipoxygenases. J. Med. Chem., 2006, 49, 1668-1683.
118. Rao, P.N.P.; Chen, Q.-H.; Knaus, E.E. Synthesis and biological evaluation of 1,3-diarylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg. Med. Chem. Lett., 2005, 15, 4842-4845.
119. Jahng, Y.; Zhao, L.-X.; Moon, Y.-S.; Basnet, A.; Kim, E.-K.; Chang, H.W.; Ju, H.K.; Jeong, T.C.; Lee, E.-S. Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activity. Bioorg. Med. Chem. Lett., 2004, 14, 2559-2562.
120. Moreau, A.; Chen, Q.-H.; Rao, P.N.P.; Knaus, E.E. Design, synthesis, and biological evaluation of (E)-3(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg. Med. Chem., 2006, 14, 7716-7727.
121. Charlier, C.; Hénichart, J.-P.; Durant, F.; Wouters. Structural insights into human 5-lipoxygenase inhibition: Combined ligand-based and target-based approach. J. Med. Chem., 2006, 49, 186-195.
122. Samuelsson, B.; Morgenstern, R.; Jakobsson, P.-J. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol. Rev., 2007, 59, 207-224.
123. Huang, X.; Yan, W.; Gao, D.; Tong, M.; Tai, H.-H.; Zhan, C.-G. Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site-directed mutagenesis. Bioorg. Med. Chem., 2006, 14, 3553-3562.
124. Fahmi, H. mPGES-1 as a novel target for arthritis. Curr. Opin. Rheumatol., 2004, 16, 623-627.
125. 2 synthase (mPGES-1) inhibitors. J. Mol. Model., 2007, 13, 601-610.
126. 2 synthase (mPGES-1) derived from MK-886. Bioorg. Med. Chem. Lett., 2005, 15, 3352-3355.
127. Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O J. Med. Chem., 2008, 51, 8068-8076
128. Werz, O.; Greiner, C.; Koeberle, A.; Hoernig, C.; George S.; Popescu, L.; Syha, Y.; Schubert-Zsilavecz, M.; Steinhilber, D. J. Med. Chem., 2008, 51, 5449-5453.
129. Côté, B.; Boulet, L.; Brideau, C.; Claveau, D.; Ethier, D.; Frenette, R.; Gagnon, M.; Giroux, A.; Guay, J.; Guiral, S.; Mancini, J.; Martins, E.; Massé, F.; Methot, N.; Riendeau, D.; Rubin, J.; Xu, D.; Yu, H.; Ducharme, Y.; Friesen, R.W. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 6816-6820.
130. Xu, D.; Rowland, S.E.; Clark, P.; Giroux, A.; Côté, B.; Guiral, S.; Salem, M.; Ducharme, Y.; Friesen, R.W.; Methot, N.; Mancini, J.; Audoly, L.; Riendeau, D. MF63 2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prosta-glandin E synthase-1 inhibitor, relieves pyresis and pain in pre-clinical models of inflammation. J. Pharmacol. Exp. Ther., 2008, 326, 754-763.
131. Pelcman, B.; Olofsson, K.; Arsenjans, P.; Ozola, V.; Suna, E.; Kalvins, I. WO Patent 077412 A1, 2006.
132. Pelcman, B.; Olofsson, K.; Schaal, W.; Kalvins, I.; Katkevics, M. Ozola, V.; Suna, E. Thienopyroles useful in the treatment of inflammation. WO Patent 042816 A1, 2007.
133. Pelcman, B.; Olofsson, K.; Harbarova, O.; Kalvins, I.; Suna, E.; Trapencieris, P.; Andrianov, V. Benzoxazoles useful in the treatment of inflammation. WO Patent 042817 A1, 2007.
134. Friesen, R.W.; Mancini, J.A. Microsomal prostaglandin E2 synthase 1 (mPGES-1): A novel anti-inflammatory therapeutic target. J. Med. Chem., 2008, 51, 4059-4067.
135. Scholich, K.; Geisslinger, G. Is mPGES-1 a promising target for pain therapy? Trends Pharmacol. Sci., 2006, 27, 399-401.